People · Operator
Named in public records as an officer, director or promoter · active 2010–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eyegate Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $72.9M | $92.6M | 2010 |
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2010 |
Paul Chaney at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Chaney on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Guyer | 1 | 8 |
| ABBIE CELNIKER | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Praveen Tyle | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Thomas Dyrberg | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| Eric Daniels | 1 | 4 |
| Peter Greenleaf | 1 | 3 |
| Thomas E. Hancock | 1 | 3 |
| Sarah Romano | 1 | 3 |
| David Hollander | 1 | 3 |
| Steven Boyd | 1 | 3 |
| Brian Strem | 1 | 2 |
| Stephen From | 1 | 2 |
| Keith Maher | 1 | 2 |
| Bernard Malfroy-Camine | 1 | 2 |
| J. Sebastien Cleiftie | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.